comparemela.com

Latest Breaking News On - Glaxosmithkline advair diskus - Page 1 : comparemela.com

Global Asthma Disease Market 2021 to Perceive Biggest Trend and Opportunity by 2028 – KSU

Vectura : highlights update made by Hikma on launch of generic Advair Diskus® Published21/04/2021 Read more

Vectura : highlights update made by Hikma on launch of generic Advair Diskus® Published21/04/2021 Read more
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

TOP NEWS SUMMARY: Netflix viewer growth de-fanged by end of lockdown

TOP NEWS SUMMARY: Netflix viewer growth de-fanged by end of lockdown Wed, 21st Apr 2021 10:56 (Alliance News) - The following is a summary of top news stories Wednesday. COMPANIES Netflix kicked off the FAANGS earnings season with a whimper, shares tumbling after-hours on Tuesday and in the pre-market Wednesday, after the video streaming giant missed membership targets. Revenue for the first quarter of 2021 grew 24% year-on-year to USD7.16 billion from USD5.77 billion, while net income surged to USD1.71 billion from USD709 million. Earnings per share also jumped to USD3.75 from USD1.57. The revenue figure was in line with the firm s beginning of quarter forecast, it said, while operating profit and margin reached all-time highs, at USD1.96 billion and 27.4% respectively. However, Netflix said it finished the quarter with 208 million paid memberships, up 14% on a year ago but below its guidance of 210 million. Paid net additions of 4 million were below its 6 million guidance. Look

LONDON BRIEFING: Bunzl holds guidance as Covid-19 related orders slow

LONDON BRIEFING: Bunzl holds guidance as Covid-19 related orders slow
lse.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lse.co.uk Daily Mail and Mail on Sunday newspapers.

Hikma resumes launch of generic Advair Diskus®

Hikma resumes launch of generic Advair Diskus® News provided by Share this article Share this article LONDON, April 20, 2021 /PRNewswire/  Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that it has resumed the launch of its generic version of GlaxoSmithKline s Advair Diskus ®1 in the US following US FDA approval of an amendment Hikma submitted to its Abbreviated New Drug Application in January 2021. The amendment reflected enhanced packaging controls to meet new industry standards adopted since the initial submission of its ANDA.  Hikma will immediately resume launch activities of its generic product for Advair Diskus ® (Fluticasone Propionate and Salmeterol Inhalation Powder, USP), 100mcg/50mcg and 250mcg/50mcg doses in the US.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.